+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis



The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis



Rheumatology 55(10): 1837-1842



To determine feasibility of TNF inhibitor (TNFi) dose reduction for severe AS and PsA patients. A retrospective study in a real-world setting. Criteria for dose reduction of TNFi included BASDAI < 4 for ⩾6 months in AS; or DAS28-ESR ⩽ 3.2 for ⩾6 months in PsA. TNFi dose was reduced by one-third. Patients who flared (BASDAI > 4 in AS or DAS28-ESR > 3.2 in PsA) were re-escalated to standard treatment dose. Twenty-six per cent (33/125) of AS and 18% (15/83) of PsA patients fulfilled criteria and underwent TNFi dose reduction. Fifty-eight per cent (19/33) of AS and 60% (9/15) of PsA patients maintained TNFi dose reduction for mean (s.d) of 1.0 (0.8) years. Reinstating standard dose of TNFi recaptured low disease activity in all patients who failed dose reduction within 24 weeks, with no statistically significant difference in mean BASDAI compared with those maintaining TNFi dose reduction in AS at 24 weeks [mean (s.d) BASDAI 2.4 (1.1) vs 1.9 (1.5), respectively (P = 0.229)]; however in PsA, those who failed dose reduction had higher disease activity compared with patients maintained on TNFi dose reduction at 24 weeks [mean (s.d) DAS28-ESR 2.7 (0.6) vs 1.3 (0.5), respectively (P ⩽ 0.001)]. In PsA, a lower DAS28-ESR prior to dose reduction of TNFi was associated with more successful dose reduction. In a real-world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNFi therapy by a third for a mean of 1 year.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059061339

Download citation: RISBibTeXText

PMID: 27354684

DOI: 10.1093/rheumatology/kew269


Related references

Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Journal of Rheumatology 36(7): 1421-1428, 2009

Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research 7(2): 155-169, 2007

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. Bmj Open 8(6): E021082, 2018

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Annals of the Rheumatic Diseases 66(10): 1393-1397, 2007

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Research and Therapy 12(3): R117, 2010

AB1120Comparison of Long-Term Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis: A Single Center Turkish Experience Over a Decade. Annals of the Rheumatic Diseases 74(Suppl 2): 1275.2-1276, 2015

FRI0353Association of Attitudes Toward Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and Tumor Necrosis Factor Inhibitors and Treatment Adherence in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: Results from the Global Align Study:. Annals of the Rheumatic Diseases 74(Suppl 2): 553.2-554, 2015

Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opinion on Biological Therapy 14(12): 1825-1836, 2014

SAT0412Patients with Psoriatic Arthritis HAD Better TNFI Survival than Ankylosing Spondylitis: HR-BO REAL Life Results. Annals of the Rheumatic Diseases 73(Suppl 2): 744.1-744, 2014

THU0141A Non-Interventional Clinical Study Evaluating The Use of Golimumab in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA), and Ankylosing Spondylitis (AS) in A Real-Life Setting in Germany. Annals of the Rheumatic Diseases 75(Suppl 2): 232.2-232, 2016

Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. International Journal of Immunopathology and Pharmacology 29(3): 510-515, 2016

Tumour necrosis factor inhibitors in ankylosing spondylitis. Internal Medicine Journal 38(10): 781-789, 2008

THU0175Adalimumab Dose Reduction in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients in Sustained Clinical Remission. Annals of the Rheumatic Diseases 73(Suppl 2): 241.2-241, 2014

Methodological concerns in tumor necrosis factor (TNF) inhibitor trials in rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS): power calculations and 1 versus 2-tailed statistical tests. 2007

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clinical and Experimental Rheumatology 34(1): 68-75, 2016